Law ME - Search Results

1

Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.

Wang M, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Ferreira RB, Chiang CW, Guryanova OA, Kopinke D, Heldermon CD, Castellano RK, Law BK. Wang M, et al. Among authors: law me. Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019. Cell Death Discov. 2019. PMID: 31839995 Free PMC article.

2

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK. Ferreira RB, et al. Among authors: law me, law bk. Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952. Oncotarget. 2017. PMID: 28423644 Free PMC article.

3

[No title available]

[No authors listed] [No authors listed] PMID: 33293526

4

Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints.

Jahn SC, Corsino PE, Davis BJ, Law ME, Nørgaard P, Law BK. Jahn SC, et al. Among authors: law me, law bk. J Cell Sci. 2013 Mar 1;126(Pt 5):1207-17. doi: 10.1242/jcs.117382. Epub 2013 Jan 15. J Cell Sci. 2013. PMID: 23321641 Free PMC article.

5

CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.

Law ME, Ferreira RB, Davis BJ, Higgins PJ, Kim JS, Castellano RK, Chen S, Luesch H, Law BK. Law ME, et al. Among authors: law bk. Breast Cancer Res. 2016 Aug 5;18(1):80. doi: 10.1186/s13058-016-0741-1. Breast Cancer Res. 2016. PMID: 27495374 Free PMC article.

6

The unfolded protein response as a target for anticancer therapeutics.

Wang M, Law ME, Castellano RK, Law BK. Wang M, et al. Among authors: law me, law bk. Crit Rev Oncol Hematol. 2018 Jul;127:66-79. doi: 10.1016/j.critrevonc.2018.05.003. Epub 2018 May 26. Crit Rev Oncol Hematol. 2018. PMID: 29891114 Review.

7

A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.

Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK. Wang M, et al. Among authors: law me, law bk. Oncogene. 2019 May;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub 2019 Feb 4. Oncogene. 2019. PMID: 30718919

8

Repurposing Tranexamic Acid as an Anticancer Agent.

Law ME, Davis BJ, Ghilardi AF, Yaaghubi E, Dulloo ZM, Wang M, Guryanova OA, Heldermon CD, Jahn SC, Castellano RK, Law BK. Law ME, et al. Front Pharmacol. 2022 Jan 13;12:792600. doi: 10.3389/fphar.2021.792600. eCollection 2021. Front Pharmacol. 2022. PMID: 35095503 Free PMC article.

9

Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.

Law ME, Yaaghubi E, Ghilardi AF, Davis BJ, Ferreira RB, Koh J, Chen S, DePeter SF, Schilson CM, Chiang CW, Heldermon CD, Nørgaard P, Castellano RK, Law BK. Law ME, et al. Cancer Lett. 2022 May 28;534:215604. doi: 10.1016/j.canlet.2022.215604. Epub 2022 Mar 2. Cancer Lett. 2022. PMID: 35247515

10

Anticancer Agents Derived from Cyclic Thiosulfonates: Structure-Reactivity and Structure-Activity Relationships.

Ghilardi AF, Yaaghubi E, Ferreira RB, Law ME, Yang Y, Davis BJ, Schilson CM, Ghiviriga I, Roitberg AE, Law BK, Castellano RK. Ghilardi AF, et al. Among authors: law me. ChemMedChem. 2022 Jul 19;17(14):e202200165. doi: 10.1002/cmdc.202200165. Epub 2022 May 23. ChemMedChem. 2022. PMID: 35491396 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters